COMPANY PROFILE

BioTissue

Explore full profile

Regenerative amniotic tissue-based products for ophthalmology, optometry, musculoskeletal and wound care markets

Miami, United StatesFounded 2001Biotech & Life Sciences

Valuation $100–250M Last recorded · 2019

Headcount 100–500 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About BioTissue

Bio-Tissue, a subsidiary of TissueTech, specializes in regenerative medicine focused on ocular surface diseases and surgical wound care. The company leverages the natural properties of human amniotic membrane tissue to promote wound healing, reduce scar formation, and control inflammation. Bio-Tissue's core products, PROKERA and AmnioGraft, are designed to support reepithelialization and improve clinical outcomes for patients. The company serves healthcare professionals, including ophthalmologists and surgeons, by providing evidence-based, FDA-recognized solutions that enhance patient satisfaction and practice growth. Operating in the ocular, surgical wound, and pain management markets, Bio-Tissue generates revenue through the sale of its specialized medical products. The business model focuses on fostering trust and delivering sustainable health economic value by addressing unmet clinical needs with differentiated solutions.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2001
Headquarters: Miami, United States
Employees: 370
Open positions: 24
Dealroom signal: 33.3/100
Industry: Health
Sub-industry: BioTechnology, Medical Devices
Sector: Biotech & Life Sciences, Rehabilitation, Biotechnology, Ophthalmology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

10 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VCOther financing	May 2021	$15M	$60M	Undisclosed	—
SERIES COther financing	Jun 2019	$35M	$141M	Essex Woodlands Health Ventures · Ballast Point Ventures	—

Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

BioTissue website traffic

Latest recorded traffic for BioTissue is 11K monthly website visits, up 41% over the last three months. BioTissue's team declined 2.4% over the past year.

Latest monthly visits11K 3-month web change+41% 1-year team growth-2.4%

Monthly website visitsOct 2017–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Director, Corporate Partnership (Remote)Miami, Florida, United States, Northern America, Americas · Human Resources · Sep 5, 2026 Business Leader, Operating Room (Southern California)Los Angeles, California, United States, Northern America, Americas · Business Development · Sep 5, 2026 Senior Director, Professional Relations & KOLMiami, Florida, United States · Human Resources · Aug 29, 2026 Representative, Sales (Minneapolis)Minneapolis, Minnesota, United States, Northern America, Americas · Sales · Aug 8, 2026 Engineer I, Product DevelopmentMiami, Florida, United States, Northern America, Americas · Business Development · Aug 1, 2026 Associate, Accounts ReceivableMiami, FL · Accounting · Aug 1, 2026 Manager, Practice Integration (Northeast)Cambridge, MA · Other · Jul 25, 2026 Specialist, Marketing OperationsMiami, FL · Marketing & Communication · Jul 16, 2026

8 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
RERetinaLogikPreventing blindness by making eye exams accessible, affordable, and detecting conditions sooner	Calgary, Canada	Operational	12	$1.4M	$2.3M
PUPulseMedicaBuilding revolutionary technology to image and treat vitreoretinal disease	Edmonton, Canada	Operational
BTBoruikang TechnologyBrain-computer interface and EEG systems used for neuroscience research and clinical neurological diagnosis	Haidian, China	Operational
NBNuVision BiotherapiesAmniotic membrane biotherapies for ocular surface disease	Nottingham, United Kingdom	Operational
STSPR TherapeuticsDevelops a temporary peripheral nerve stimulation system for non-opioid pain management.	Cleveland, United States	Acquired
BNBlackrock NeurotechManufactures a wide range of scientific equipment to record bio-potentials from the central and peripheral nervous system in both chronic and acute applications	Salt Lake City, United States	Acquired
SYSynchronDeveloping implantable brain-computer interfaces to restore neurological function and enable direct communication between the brain and external devices	New York City, United States	Operational
HVHelio VisionHelio Vision develops a therapy for rare, fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery	Lexington, United States	Acquired